Doctor Andres Bruno

17/08/2022

HBV-positive and HIV-positive organs in transplantation: A clinical guide for the hepatologist

Transplantation from donors positive for HBV and HIV has increased in many countries. The intentional transmission of a virus has practical, ethical, and clinical implications. In this review, Russo and colleagues summarise the current research, focusing on grafts from donors positive for the HBV surface antigen, antibodies against the HBV core antigen, and HIV, to help hepatologists and physicians interested in transplantation to select the best antiviral and/or prophylactic regimens for after transplantation.

Full review here 👉https://bit.ly/3O04Z14

13/11/2020

A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA. Read open access at bit.ly/2UomNZa

In patients with primary biliary cholangitis (PBC) the utility of budesonide is unresolved. In a placebo-controlled, double-blind trial, this study evaluated the added-value of budesonide in those with PBC and ongoing risk of progressive disease despite ursodeoxycholic acid (UDCA). Budesonide did not associate with improvement in liver histology; improvements in biochemical markers of disease activity were demonstrated in secondary analyses.

06/08/2020

High rates of 30-day mortality in patients with cirrhosis and COVID-19. Full text at https://bit.ly/2YiTybo

Coronavirus disease 2019 (COVID-19) poses a major health threat to healthy individuals and those with comorbidities. This study assessed its impact on patients with cirrhosis. Infection with COVID-19 was associated with liver function deterioration and elevated mortality in patients with cirrhosis.

04/08/2020

03/08/2020

Epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis. bit.ly/2A4DPo1

Sudden damage to the kidneys is becoming more common in people who are hospitalized and have cirrhosis. Despite advances in cirrhosis care, a significant gap remains in outcomes between cirrhotics with and without acute kidney injury. Acute kidney injury continues to represent a major clinical challenge.

13/08/2019

Portal hypertension contributes to the pathogenesis of malnutrition and sarcopenia in cirrhosis via multiple mechanisms. Terlipressin is a vasopressin analogue that we administer via continuous outpatient infusion, as a bridge to transplantation in patients with hepatorenal syndrome or refractory as...

11/07/2019

The page or action you requested has resulted in an error. Please go back to the previous page by using your browser's Back button, or visit the Home Page.

13/06/2019

14/03/2019

Gastroesophageal varices are significant challenges that are commonly faced by patients with cirrhosis.1 Variceal hemorrhage occurs in 10–15% of patients annually depending on the size of varices, the presence of red wale marks, and the severity of liver disease.2 In addition, acute variceal hemor...

23/01/2019

Inflammatory pathways in alcoholic steatohepatitis

Inflammatory processes are primary contributors to the development and progression of alcoholic steatohepatitis. Herein, the authors review the roles of multiple cell types that are involved in inflammation in ASH and highlight the concept that inflammation also plays an important role in promoting liver repair and controlling bacterial infection. Understanding the complex regulatory processes that are disrupted during the progression of ASH will likely lead to better-targeted strategies for therapeutic interventions.

https://www.journal-of-hepatology.eu/article/S0168-8278(18)32507-8/fulltext

09/11/2018

Most patients with chronic hepatitis C virus (HCV) infection have either already received antiviral treatment or are expected to receive treatment with direct-acting antivirals (DAAs) in the next 3–5 years in the United States. With sustained virologic response (SVR) rates well in excess of 90%,...